Eli Lilly On More Equal Footing With Rival With Weight-Loss Pill -- Market Talk

Dow Jones04:09

1609 ET - Eli Lilly is back on a more level playing field with rival Novo Nordisk after getting Food and Drug Administration approval for its once-daily oral GLP-1 pill Foundayo, also known as orforglipron, Morgan Stanley analysts say in a note. Foundayo does not require food or water restrictions, and follows Novo Nordisk's launch of oral Wegovy earlier this year, the analysts say. But to meet consensus estimates for U.S. sales of about $1.45 billion in 2026, Eli Lilly's orforglipron launch would need to ramp to higher volumes than recent GLP-1 launches, the analysts say. They forecast the drug will generate about $1.2 billion in sales this year. (kelly.cloonan@wsj.com)

(END) Dow Jones Newswires

April 02, 2026 16:09 ET (20:09 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment